CRISPR-screens revealed that loss of AHR and PARP7 protect against the antiproliferative effects of RBN2397 [25, 29], while RBN2397 in combination with AHR activation synergistically increases sensitivity to RBN2397 across several cancer cell lines [30]. Here, TIPARP is linked to cancer.